These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37201081)

  • 1. Immune checkpoint inhibitors in liver transplant: a case series.
    Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
    J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
    Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
    Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    Rezaee-Zavareh MS; Yeo YH; Wang T; Guo Z; Tabrizian P; Ward SC; Barakat F; Hassanein TI; Dave S; Ajmera V; Bhoori S; Mazzaferro V; Chascsa DMH; Liu MC; Aby ES; Lake JR; Sogbe M; Sangro B; Abdelrahim M; Esmail A; Schmiderer A; Chouik Y; Rudolph M; Sohal D; Giudicelli H; Allaire M; Akce M; Guadagno J; Tow CY; Massoumi H; De Simone P; Kang E; Gartrell RD; Martinez M; Paz-Fumagalli R; Toskich BB; Tran NH; Solino GA; Poltronieri Pacheco DM; Kalman RS; Agopian VG; Mehta N; Parikh ND; Singal AG; Yang JD
    J Hepatol; 2025 Jan; 82(1):107-119. PubMed ID: 38996924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and transplantation for hepatocellular carcinoma.
    Tabrizian P; Abdelrahim M; Schwartz M
    J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.
    Tabrizian P; Holzner ML; Ajmera V; Kim AK; Zhou K; Schnickel GT; Torosian K; Hoteit M; Marino R; Li M; Yao F; Florman SS; Schwartz ME; Mehta N
    J Hepatol; 2024 Sep; ():. PubMed ID: 39255928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report.
    Ohm H; Khwaja R; Karachiwala H
    J Gastrointest Oncol; 2023 Dec; 14(6):2644-2649. PubMed ID: 38196545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?
    Pahari H; Peer JA; Tripathi S; Singhvi SK; Dhir U
    World J Gastrointest Pharmacol Ther; 2024 Sep; 15(5):97570. PubMed ID: 39281264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
    Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.
    De Stefano N; Patrono D; Colli F; Rizza G; Paraluppi G; Romagnoli R
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang J; Huang H; Chen R; Lin Y; Ling Q
    Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant.
    Liu MC; Lizaola-Mayo B; Jayasekera CR; Mathur AK; Katariya N; Aqel B; Byrne TJ; Chascsa DMH
    J Gastrointest Cancer; 2024 Jun; 55(2):969-974. PubMed ID: 38483692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal graft-versus-host disease in recipient with pretransplant exposure to immune checkpoint inhibitors and donor-dominant one-way HLA matching after liver transplantation: A case report.
    Pang L; Wu WR; Xu LB; Liu C
    Int J Surg Case Rep; 2024 Oct; 123():110267. PubMed ID: 39265369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy.
    Chouik Y; Erard D; Demian H; Schulz T; Mazard T; Hartig-Lavie K; Antonini T; Mabrut JY; Mohkam K; Rode A; Merle P
    Front Immunol; 2023; 14():1205997. PubMed ID: 37377975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
    Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
    Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.
    Gao Q; Anwar IJ; Abraham N; Barbas AS
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.
    Luo Y; Teng F; Fu H; Ding GS
    World J Gastrointest Oncol; 2022 Jan; 14(1):163-180. PubMed ID: 35116109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.
    Anugwom CM; Leventhal TM; Debes JD
    Hepatoma Res; 2022; 8():. PubMed ID: 35693455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
    Hu B; Yang XB; Sang XT
    Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.